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Abstract
Background: Recent studies have identified HIV infection as a potential risk factor for invasive meningococcal
disease (IMD), suggesting that HIV-infected individuals could benefit from meningococcal vaccination to reduce
their risk of this rare, but severe and potentially fatal infection. In the United Kingdom, as in most industrialised
countries, HIV is not considered a risk factor for IMD.
Methods: IMD incidence and relative risk by age group and meningococcal capsular group in HIV-positive
compared with HIV-uninfected individuals was estimated through data linkage of national datasets in England
between 2011 and 2013.
Results: IMD incidence among persons diagnosed with HIV was 6.6 per 100,000 compared to 1.5 per 100,000
among HIV-negative individuals, with a relative risk of 4.5 (95 % CI, 2.7–7.5). All but one case occurred in adults
aged 16–64 years, who had a 22.7-fold (95 % CI, 12.4–41.6; P <0.001) increased risk compared with the HIV-negative
adults. IMD risk by capsular group varied with age. HIV-positive children and adolescents had a higher risk of
meningococcal group B disease, while adults were at increased risk of groups C, W and Y disease. Most HIV-positive
individuals had been born in Africa, had acquired HIV through heterosexual contact, and were known to be
HIV-positive and receiving antiretroviral treatment at IMD diagnosis. The most common clinical presentation
was septicemia and, although intensive care admission was common, none died of IMD.
Conclusions: HIV-positive children and adults are at significantly increased risk of IMD, providing an evidence base for
policy makers to consider HIV as a risk factor for meningococcal vaccination.
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Background
Neisseria meningitidis, commonly known as the menin-
gococcus, is a major global cause of meningitis and
septicaemia, and is associated with significant morbidity
and mortality across all age groups [1]. Twelve distinct
polysaccharide capsules have been described, includ-
ing five that are responsible for almost all cases of
invasive meningococcal disease (IMD) globally: A, B,
C, W and Y [1].
In the United Kingdom, as in most of Europe, menin-
gococcal groups B (MenB) and C (MenC) were previ-
ously responsible for nearly all IMD cases [2]. Invasive
MenC disease, however, is now uncommon since routine
vaccination against MenC was introduced in 1999, with
most cases now occurring in unvaccinated adults who
acquire the infection abroad [2]. MenB, therefore, has
been responsible for 80–90 % of all IMD cases, with the
highest incidence in infants (<1 year-olds) and toddlers
(1–4 year-olds), and with a small secondary peak in
adolescents and young adults [3]. Meningococcal groups
W (MenW) and Y (MenY) are uncommon and mainly
cause disease in older adults, although the UK is currently
experiencing a national outbreak of MenW disease across
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all age groups, following endemic expansion of a single
hypervirulent strain belonging to the ST-11 clonal
complex [4].
Unlike older adults (≥65 year-olds), the vast majority
of children and young adults who develop IMD are
previously healthy. The only significant risk factors for
IMD are complement deficiency and asplenia/splenic
dysfunction [5]. These risk groups are currently advised to
receive the meningococcal quadrivalent conjugate vaccine
(MenACWY) and the recently licensed multi-component
protein-based MenB vaccine (Bexsero®, Novartis, Basel,
Switzerland). They may also be on penicillin prophylaxis,
which should provide additional protection against IMD
[5]. Both these vaccines will be included in the UK na-
tional infant and adolescent immunisation programmes,
respectively, later this year [5].
Unlike other encapsulated bacteria, such as Streptococcus
pneumoniae and Haemophilus influenzae type b (Hib),
immunosuppression (primary or acquired) has not been
considered a significant risk factor for IMD [5]. Although
the British HIV Association (BHIVA) testing guidelines
recommend the quadrivalent vaccine containing A, C, W
and Y, for travellers considered to be at risk or in contact
with these capsular groups [6], HIV-positive individuals
are not recommended to receive any additional vaccina-
tions against IMD apart from the scheduled routine MenC
doses, irrespective of their degree of immunosuppression
or HIV treatment status [7–13].
The objective of this study was to assess the risk of
IMD by age and capsular group in persons diagnosed
with HIV in England. Analysis was performed using na-
tional data for the three most recent years, with the
aim of developing an evidence base for recommending
meningococcal vaccination for this vulnerable group.
Methods
Meningococcal surveillance
Public Health England (PHE) conducts enhanced na-
tional surveillance of IMD and captures more than 95 %
of laboratory-confirmed cases in England [3]. As part of the
enhanced surveillance, the PHE Meningococcal Reference
Unit (MRU) provides a national service for species confirm-
ation and grouping/typing of invasive N. meningitidis
isolates, which are not routinely performed by National
Health Service (NHS) hospital laboratories. The MRU
also offers free PCR testing for meningococcal DNA in
clinical specimens (e.g. blood, cerebrospinal fluid, joint
fluid, pleural fluid), which are routinely submitted by
NHS hospital laboratories throughout England [3]. Species
confirmation and capsular group determination were per-
formed as described previously [14]. Since 1 January 2011,
all laboratory-confirmed cases are followed-up by request-
ing the patient’s general practitioner (GP) to complete a
short questionnaire requesting information on risk factors,
co-morbidities, clinical presentation, complications and
outcome of IMD.
HIV surveillance
In addition to the information collected through GP
questionnaires, all confirmed cases of IMD were matched
to all persons newly diagnosed with HIV between 1981
and 2013, collected through a comprehensive national
cohort of persons presenting for an HIV test across all
testing facilities in England and subsequently accessing
HIV care. Details of the HIV surveillance systems are
detailed on the PHE website [15–17]. Cases of menin-
gococcal disease were linked to persons diagnosed with
HIV using soundex code (pseudo-anonymised coding
of surname), initial, date of birth, sex and region of
diagnosis. Data available on persons diagnosed with
HIV are estimated to represent 76 % of all persons liv-
ing with HIV, with around a quarter of persons living
with HIV currently unaware of their infection. Reports
of new HIV diagnoses for the study period, January
2011 to December 2013, are likely to be complete, with
minimal reporting lag after two years.
Ethics agreement for this work is not required under
the provisions in regulation 3 of The Health Service
(Control of Patient Information) Regulations 2002, which
authorises patient information to be processed by persons
employed or engaged for the purposes of the health service
or other persons employed or engaged by a government
department or other public authority in communicable
disease surveillance or associated with other risks to
public health [18]. All data collected was under the remit
of communicable disease surveillance.
Population
The study population consisted of all persons with
confirmed IMD in England between January 2011 and
December 2013. IMD cases were matched to persons
diagnosed with HIV to identify all potential co-infected
persons using soundex, initials, date of birth and sex. Con-
firmed meningococcal cases who were not identified by
their GPs to be HIV-positive and who did not link to the
HIV database were considered to be HIV-uninfected.
Definitions
Invasive meningococcal disease was defined as either
isolation of N. meningitidis or DNA detection by PCR
from a normally sterile body site [3].
A CD4 cell count reported within 90 days either side
of HIV diagnosis was defined as the CD4 count at HIV
diagnosis. A CD4 cell count below 350 cells/mm3 was
defined as the time after which HIV treatment should
have been commenced [6]. Therefore, any person with a
CD4 cell count below 350 cells/mm3 was defined as hav-
ing been diagnosed late. The CD4 cell count and ART
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status at IMD diagnosis among those co-infected was in-
cluded if within 90 days of IMD diagnosis.
Statistical analysis
Statistical analyses were performed using STATA version
10 (Stata Corp., College Station, TX, USA). IMD incidence
for persons diagnosed with HIV was calculated using the
national cohort of persons diagnosed and living with HIV
[16]. IMD incidence for the general population was calcu-
lated using population denominators from the Office for
National Statistics (www.statistics.gov.uk). The overall and
age-specific HIV-uninfected population were defined as
the difference between the general population and the
number of diagnosed HIV-positive persons. Incidence was
calculated for all IMD, capsular group-specific (B, C, W
and Y) and vaccine-preventable (B and ACWY) IMD.
Relative risk of IMD in HIV-positive compared with
HIV-uninfected individuals was calculated using the in-
cidence of these measures in co-infected and uninfected
persons over the study period. Rates were compared using
Pearson’s x2 test. Proportions were compared using the x2
test or Fisher’s exact test, as appropriate. Using a backwards
logistic regression model, we examined factors associated
with being co-infected with IMD and HIV. Variables
included sex, age group, capsular group and clinical
presentation. All confidence intervals (CI) are at the
95 % significant level.
Results
During 2011–2013, there were 2,353 confirmed IMD
cases in England. The highest number of cases occurred
in infants (<1 year-olds) who accounted for 21 % (499/
2,345) of cases over the three-year period. IMD cases de-
clined after the first year of life, although children less
than 5 years old still accounted for nearly half of all
cases (1,145/2,345, 49 %). A smaller peak was observed
in adolescence, starting at 16 years and peaking at
19 years, before declining. MenB was responsible for
92 % (1,266/1,371) of cases in <16 year-olds, 68 % (480/
703) in 16–64 year-olds and 41 % (96/237) in ≥65 year-
olds. Meningococcal groups A, C, W and Y were re-
sponsible for 7.7 % (n = 105), 32 % (n = 222) and 59 %
(n = 141) cases in these age groups, respectively.
Demographics
Co-infection with IMD and HIV was identified in 14
cases. Eleven were known to be HIV-positive prior to
IMD with a median time of 6.5 (IQR, 2.5–10.6) years
between HIV diagnosis and IMD diagnosis, two were
diagnosed with HIV when they developed IMD, and
one developed IMD one year prior to being confirmed
as HIV-positive. All but one IMD case (93 %) among
HIV-positive individuals were in adults aged 16–64
years (Table 1).
Incidence
The mean annual IMD incidence during 2011–2013 was
6.6 per 100,000 persons diagnosed with HIV compared
with 1.5 per 100,000 among HIV-uninfected persons
(relative risk, 4.5; 95 % CI, 2.7–7.5; P <0.001) (Table 2).
The higher risk was observed for all three calendar years
and across all age groups except older adults, where no
IMD cases occurred in the HIV-positive cohort. When
analysed by capsular group, the relative risk of IMD in
adults was significantly higher for MenC, MenW and
MenY (Table 3). An increased risk for MenB disease
was only observed among adolescents and young adults
(16–24 year-olds). For the other capsular groups,
MenACWY were responsible for 31 % (212/690) of
IMD cases in HIV-uninfected adults (16–64 year-olds)
compared with 77 % (10/13) in those diagnosed with HIV,
who had a 22.7-fold (95 % CI, 12.4–41.6; P <0.001) in-
creased risk of IMD caused by these capsular groups.
In children, although there was only a single case of
MenB in three years, this still constituted an increased
relative risk of 10.0 (95 % CI, 1.4–71.1; P = 0.005) for in-
vasive MenB disease compared with HIV-uninfected
children.
Risk factors in persons diagnosed with HIV
Of the 14 HIV-positive individuals who developed IMD,
71 % had acquired HIV through heterosexual contact,
14 % through mother-to-child transmission (MTCT)
and 14 % were men who have sex with men (MSM)
(Table 4). IMD incidence was highest in those infected
through MTCT (44.8 per 100,000 MTCT), compared
with 9.4 per 100,000 heterosexuals diagnosed with HIV
and 2.1 per 100,000 MSM.
Eight of the ten persons who acquired HIV through
heterosexual contact and all persons infected through
MTCT were born in Africa, resulting in an incidence of
IMD among those diagnosed with HIV born in Africa
being almost four times higher (IRR, 3.76; 95 % CI,
0.97–21.24) than that among those born in the UK (15.0
per 100,000 vs. 4 per 100,000).
Of the 11 persons diagnosed with HIV before developing
IMD, the CD4 count, where reported, was <350 cells/mm3
in 50 % at HIV diagnosis (5/10) and at IMD diagnosis (4/8),
and nearly all were on ART when they developed IMD
(8/10). Of the five persons with a CD4 count of <350
cells/mm3 at HIV diagnosis, 75 % (3/4) continued to
have a CD4 count of <350 cells/mm3 at IMD diagnosis,
although all were receiving ART. The two adults diag-
nosed with HIV when they developed IMD had CD4
counts <350 and >350 cells/mm3, respectively, while the
only case diagnosed with HIV more than one year after
developing IMD had a CD4 count <350 cells/mm3.
Only 2 of the 14 cases had received a meningococcal
vaccine prior to developing IMD, one was eligible for
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the MenC conjugate vaccine as part of the national
MenC catch-up campaign during 1999–2000 but de-
veloped MenW disease, and the other had received the
ACWY vaccine abroad and subsequently developed
MenW disease. The three UK-born individuals were
too old to have been eligible for any meningococcal
vaccination.
The most common clinical presentation was septicaemia,
followed by meningitis and pneumonia. Adjusting for age,
gender and capsular group in a multivariable logistic
Table 1 Distribution of persons with laboratory-confirmed invasive meningococcal disease (IMD) by HIV status in England
during 2011–2013
Persons diagnosed with HIV Uninfected persons
n = 14 % n = 2,339 %
Age at meningococcal infection (years)
<16 1 7.1 1,395 59.8
16–24 3 21.4 314 13.5
25–44 5 35.7 159 6.8
45–65 5 35.7 225 9.7
≥65 0 0 238 10.2
Not reported 8
Median age at IMD (IQR) 32 (24–48) 5 (1–29)
Sex
Male 7 50 1,166 50.2
Female 7 50 1,159 49.8
Not reported 14
Year of meningococcal diagnosis
2011 6 42.9 880 37.6
2012 3 21.9 738 31.6
2013 5 35.7 721 30.8
Region of meningococcal diagnosis
East of England 0 0 178 7.6
East Midlands 1 7.1 205 8.8
London 7 50.0 329 14.1
North East 0 0 156 6.7
North West 4 28.6 459 19.6
South East 2 14.3 307 13.1
South West 0 0 226 9.7
West Midlands 0 0 237 10.1
Yorkshire and the Humber 0 0 242 10.3
Meningococcal group
A 0 0 1 0.0
B 4 28.6 1,841 78.7
C 3 21.4 81 3.5
W 2 14.3 146 6.2
Y 5 35.7 235 10.0
Other/non-groupable 0 0 35 1.5
Died
Yes 0 0 150 6.4
No 14 100 2,189 93.6
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regression model, clinical presentation was not significantly
different for HIV-positive compared to HIV-uninfected
cases. Although 6/14 (43 %) required intensive care
support, no HIV infected people died of IMD.
Discussion
During a period when ART was routinely available in
England, persons diagnosed with HIV had a 4.8-fold in-
creased risk of IMD compared with individuals not
known to be HIV infected. This increased risk was al-
most entirely in adults aged 16–64 years (23-fold in-
creased risk) and was significant for Men C, W and Y,
while MenB was only significant in those aged 16–24
years. There was only one MenB case in children with
HIV and no cases in ≥65 year-olds. Most patients were
born outside the UK, were known to be HIV-positive
and receiving ART at the time of infection, and had
not received any meningococcal vaccination prior to
developing IMD.
These findings are consistent with the most recent
study from New York City (NYC) where the relative risk
for IMD among people living with HIV/AIDS (PLHIV)
during the ART era was 10.0 especially among those
with a CD4+ count of less than 200 cells/mm3 [13]. Not-
ably, we observed a 15.9-fold increased risk for MenC,
MenW and MenY, which are all potentially preventable
through immunisation with the MenACWY quadrivalent
conjugate vaccine [19]. The NYC study also found these
capsular groups to be more prevalent among HIV-infected
adults with IMD (87 %) compared to the IMD-only group
(72 %), although the difference was not statistically signifi-
cant. An earlier study from the United States also reported
a significantly higher risk of IMD in HIV-positive adults
[7] and these findings were corroborated in a large South
African study, where the age-adjusted relative risk of de-
veloping IMD was 11.3, with a two-fold increased risk of
dying from the infection [8]. Other studies from develop-
ing countries with high HIV prevalence, however, have
not found any significant associations with IMD [9–12].
In HIV-uninfected individuals, half of all IMD cases in
England are diagnosed in children younger than 5 years
and more than 90 % of cases in this age group are
caused by MenB [3]. Although only one IMD case was
diagnosed among children with HIV, this single case
represented a significantly higher risk for HIV-positive
children when compared with HIV-uninfected children.
In adolescents, a small peak in IMD coincides with
teenagers entering higher education settings (typically
universities), where they are exposed to lifestyle factors
and behaviors that increase their risk of IMD, such as
smoking (or being exposed to smoke), kissing, sharing
drinking glasses, eating utensils or water bottles, and living
in close quarters (e.g. dormitories) [20]. Overall, MenB is
still responsible for the majority (85–90 %) of IMD cases
in adolescents. In HIV-positive persons, the increased risk
in invasive MenB disease was only observed among 16–24
year-olds. In contrast, the risk of MenW and MenY dis-
ease was significantly higher across all adult age groups.
These two capsular groups are uncommon causes of IMD
in England and generally considered to be less virulent
Table 2 The incidence of invasive meningococcal disease (IMD) and relative risk by demographics for persons diagnosed with HIV
and for the uninfected population in England during 2011–2013
Persons diagnosed with HIV Uninfected population
Cases Person-years Incidence Cases Person-years Incidence Relative risk 95 % CI P value
Overall 14 213,725 6.6 2,339 160,252,992 1.5 4.5 (2.7, 7.5) <0.001
Age at meningococcal infection (years)
<16 1 2,415 41.4 1,395 30,366,823 4.6 9.0 (1.3, 64.0) 0.008
16–24 3 6,703 44.8 314 18,760,191 1.7 26.5 (8.6, 81.8) <0.001
25–44 5 113,183 4.4 159 43,536,541 0.4 11.8 (5.0, 27.9) <0.001
45–65 5 84,462 5.9 225 40,505,320 0.6 10.4 (4.4, 24.9) <0.001
≥65 0 6,962 0.0 238 27,084,317 0.9
Not reported 8
Sex
Male 7 142,479 4.9 1,166 78,858,090 1.5 3.3 (1.6, 6.9) <0.001
Female 7 71,246 9.8 1,159 81,394,902 1.4 6.9 (3.3, 14.4) <0.001
Not reported 14
Year of meningococcal diagnosis
2011 6 67,649 8.9 880 53,039,551 1.7 5.3 (2.4, 11.8) <0.001
2012 3 71,316 4.2 738 53,422,384 1.4 3.0 (1.0, 9.4) 0.043
2013 5 74,760 6.7 721 53,791,057 1.3 5.0 (2.1, 11.9) <0.001
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than MenB or MenC, causing disease mainly in older
adults who often have underlying co-morbidities [4, 21]. A
notable feature of these two capsular groups is the atypical
clinical presentation, including respiratory tract infections
such as pneumonia, epiglottitis, cellulitis and septic
arthritis [22]. If IMD is not considered in the differential
diagnosis, then public health actions to offer rapid chemo-
prophylaxis and the MenACWYconjugate vaccine to close
contacts (who may also be HIV-positive) could be delayed
and lead to secondary cases.
Although we observed significantly higher rates of cap-
sular group-specific IMD in HIV-positive individuals,
there were only 14 cases diagnosed over the three-year
period, equivalent to 0.5 % of all IMD cases. In this
high-risk group, however, we found that most individuals
had acquired HIV through heterosexual contact and the
incidence in MSM was similar to the background rate. A
recent MenC disease outbreak in NYC was reported among
MSM and subsequently identified in other countries,
including Germany and France, resulting in an offer of
vaccination against MenC to MSM in these countries
[13, 23–28]. In England, there were no cases of MenC
disease in children, adolescents or young adults (<25 year-
olds) with HIV over the three-year period and none
among MSM of any age, highlighting the success of the
current national MenC conjugate vaccination programme
in providing both direct and indirect protection against
MenC disease [29].
Unlike the US, MenB is responsible for most IMD
cases in children and adults in England. The significantly
higher risk of MenC, MenW and MenY disease among
persons diagnosed with HIV in England is, therefore, in-
triguing. Most cases were known to be HIV-positive at
IMD diagnosis and half of them continued to have low
CD4 counts at IMD diagnosis, making them generally
susceptible to serious bacterial infections, including the
less virulent meningococcal capsular groups such as MenW
and MenY. In persons known to be HIV-positive, we found
no association between IMD and CD4 counts at HIV
diagnosis, time since HIV diagnosis, CD4 counts at IMD
Table 3 Incidence of invasive meningococcal disease (IMD) in adults and relative risk by HIV status and capsular group in England
during 2011–2013
Incidence of meningococcal
Capsular group Age group (years) Persons co-infected with HIV Uninfected persons Rate ratio 95 % CI P value
All All 6.6 1.4 4.5 (2.7, 7.7) <0.001
16–24 44.8 1.7 26.8 (8.7, 82.8) <0.001
25–44 4.4 0.4 11.9 (5.0, 28.2) <0.001
45–64 5.9 0.6 10.5 (4.4, 25.1) <0.001
ACYW All 4.7 0.3 16.0 (8.7, 29.6) <0.001
16–24 29.9 0.4 73.7 (18.8, 289.4) <0.001
25–44 3.5 0.1 26.6 (10.3, 68.5) <0.001
45–64 4.7 0.2 21.8 (8.4, 56.9) <0.001
B All 1.9 1.1 1.6 (0.6, 4.3) 0.32
16–24 14.9 1.3 11.8 (1.7, 83.6) 0.002
25–44 0.9 0.2 3.7 (0.5, 26.1) 0.16
45–64 1.2 0.3 3.5 (0.5, 24.4) 0.19
C All 1.4 0.05 27.1 (8.9, 82.4) <0.001
16–24 - 0.1 - - -
25–44 1.8 0.05 35.1 (9.4, 131.4) <0.001
45–64 1.2 0.03 32.0 (4.8, 212.8) <0.001
Y All 2.3 0.1 15.8 (6.7, 37.7) <0.001
16–24 14.9 0.2 73.7 (10.7, 509.9) <0.001
25–44 0.9 0.1 15.4 (2.3, 105.3) <0.001
45–64 3.6 0.1 32.0 (10.7, 95.6) <0.001
W All 0.9 0.1 10.2 (2.6, 40.5) <0.001
16–24 14.9 0.1 107.7 (15.8, 736.3) <0.001
25–44 0.9 0.02 35.1 (5.4, 227.2) <0.001
45–64 0.0 0.1 - - -
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diagnosis or receiving ART at IMD diagnosis. Given that
most cases had been born outside the UK, it is likely that
they were at higher risk of exposure to infection when
they themselves, their close family or community contacts
travelled to their country of origin. It is also possible that
these cases socialise in highly-defined closed networks –
either because of their HIV infection or because of their
ethnic background – where the less common meningococ-
cal capsular groups may be circulating.
Limitations
Until now, except for complement deficiency and splenic
dysfunction, HIV or any other immune deficiency has
not been considered a significant risk factor for IMD [5].
In the current study, too, only 0.5 % of IMD cases were
known to be HIV-positive. However, the IMD surveil-
lance questionnaires were completed by GPs, who are
not always aware of the diagnosis of HIV. It is, therefore,
possible that HIV prevalence among IMD patients may
be underestimated as demonstrated by the additional as-
certainment through linkage with the national HIV data-
base. In children, however, there were limited identifiers
in the HIV database for linkage compared to adults and,
therefore, some children with HIV and IMD may have
been missed. It is also not possible to estimate the
number of undiagnosed HIV-positive cases in the IMD
cohort because the latter are not routinely tested for
HIV. Furthermore, it is estimated that a quarter of per-
sons estimated to be living with HIV are unaware of
their infection and would not be included within the
national cohort of persons accessing HIV care. How-
ever, the coverage of persons diagnosed and utilising
HIV-related care indicates high rates of access to care
and low rates of loss to follow-up [30]. Moreover, iden-
tifying additional HIV-positive individuals among IMD
cases would only serve to strengthen the association
between HIV and IMD, and increase the estimated relative
risks further.
Clinical implications
A protein-based, multi-component MenB vaccine has
recently been licensed in Europe and will be introduced
into the UK infant immunisation programme in 2015 [31].
This vaccine induces high concentrations of bactericidal
antibodies against most MenB strains causing IMD in the
UK and could potentially also protect against other menin-
gococcal capsular groups [32]. HIV-infected infants born in
the UK will, therefore, benefit from the vaccine programme,
although there are currently very few infants infected
through MTCT because of the high uptake of antenatal
screening and very high effectiveness of antenatal and peri-
natal ART in preventing MTCT from mothers known to be
HIV-positive [33]. Older children with HIV, including
newly diagnosed entrants to the UK, would not be eli-
gible for MenB vaccination because there is no catch-up
programme planned for the UK. Reassuringly, though,
invasive MenB disease is much less common in older
children irrespective of HIV status.






















<16 B 2 years 2 years N N MTCT Africa 2008 Septicaemia N
16–24 W 13 years - N/A N/A MTCT Africa 2000 Pneumonia Y
16–24 B After IMD After IMD Y N/A MSM Asia 2008 Men & Sep Y
16–24 Y 2 years 2 years Y N HET Africa 2004 Men & Sep Y
25–44 Y 11 years 11 years Y Y HET Africa 2002 Septic
arthritis
N
25–44 C 9 years 9 years N N HET Africa 2000 Septicaemia N
25–44 W 8 years 8 years N N HET Africa 2004 Septicaemia Y
25–44 B 5 years 4 years Y Y HET Africa 2004 Septicaemia N
45–64 C 5 years At time of IMD N N/A MSM UK - Septicaemia N
45–64 Y 16 years 2 years N Y HET UK - Pneumonia N
45–64 Y 10 years At time of IMD Y N/A HET Africa 1988 Septicaemia Y
45–64 B 3 years 3 years Y Y HET Africa 2002 Meningitis N
45–64 Y At the time
of IMD
After IMD N N HET Africa 1975 Men & Sep Y
45–64 C At the time
of IMD
Not on ART Y Y HET UK - Septicaemia N
HET heterosexual contact, ICU intensive care unit, Men & Sep meningitis and septicaemia, MSM men who have sex with men, MTCT mother-to-child transmission,
N no, N/A not available, Y yes
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In adolescents and young adults, the recent increase in
invasive MenW disease in England caused by a hypervir-
ulent clonal complex (cc11) clone has led to recommen-
dations for a national adolescent MenACWY conjugate
vaccination programme for 14–18 year-olds, which will
be introduced imminently [34]. This programme should,
therefore, also protect HIV-positive individuals of all
ages against these four capsular groups through both
direct and indirect (herd) protection. The potential high
level of exposure to meningococcal for infected individ-
uals born overseas, however, may be less amenable to
prevention by a UK-based programme and may reflect
a substantially higher risk in uninfected people with
overseas origins.
The MenACWY conjugate vaccine, however, will not
protect against MenB disease. Future studies on the
immunogenicity of the recently licensed MenB vaccine
in HIV-positive children and adolescents at different
stages of immunosuppression and antiretroviral treatment
could potentially support recommendations for MenB
vaccination in these age groups. Our results also indicate
that newly diagnosed adults with HIV may benefit from
MenACWY conjugate vaccination [19, 35]. However,
the wide range of CD4 counts, including a significant
proportion with very low counts, and the variable duration
and combinations of ART at the time of IMD diagnosis
suggest that these parameters may not be useful criteria
for recommending the most appropriate timing for men-
ingococcal vaccination. Current UK guidelines suggest
that vaccination should be given to persons with CD4
counts <200 cells/mm3 if indicated and safe, and repeated
following immunoreconstitution if required [36].
There are three available MenACWY vaccines, each
conjugated to a different carrier protein, and one
(MenACWY-D; Menactra®, Sanofi Pasteur, Lyon, France)
has been assessed in HIV-positive children and adolescents;
the vaccine was immunogenic against the four capsular
groups and a two-dose elicited higher bactericidal antibody
concentrations and protected more individuals than a sin-
gle dose [19, 37]. Vaccine responses were dependent on
age, the presence of an AIDS-defining illness, CD4 count
and HIV viral load [19, 35, 37], although none of these
factors were consistently predictive of poorer antibody
responses. Unlike the UK, a two-dose MenACWY primary
MenACWY conjugate vaccine schedule, given at least
2 months apart, is recommended for HIV-positive adoles-
cents (>11 years) in the US, with boosters every 5 years
[38]; notably, the recently licensed MenB vaccines have
been recommended for those considered at increased risk
of MenB disease but not for HIV-positive individuals [39].
Another important observation was that HIV diagno-
sis was known at the time of IMD for nearly all cases. In
only two patients was the diagnosis of HIV made at the
time of IMD infection and, in one case, after recovering
from IMD, highlighting the importance of considering
an underlying diagnosis of HIV if clinically indicated, in-
cluding but not limited to immigration from an HIV-
endemic area, intravenous drug use or MSM, history of
opportunistic infections or low lymphocyte counts when
hospitalised for IMD.
Availability of data and materials
All data for persons co-infected with HIV and invasive
meningococcal disease are available within the Table 4.
Further requests regarding individual participant data
should be made to the clinical leads, Dr Shamez Ladhani
for meningococcal (shamez.ladhani@phe.gov.uk) and Dr
Valerie Delpech for HIV (valerie.delpech@phe.gov.uk).
Conclusion
This study provides evidence that HIV-positive children
and adults are at increased risk of IMD, up to five times
higher than the general population. Furthermore, the
risk among the capsular groups MenC, MenW, and
MenY, preventable through the MenACWY quadrivalent
conjugate vaccine, was 16 times higher in adults, espe-
cially 16-24 year-olds who had a much higher risk. These
findings provide an evidence base for policy makers to
include HIV as a risk factor for meningococcal vaccin-
ation, and clinicians to consider HIV as a possible
underlying condition in children and adults who develop
invasive meningococcal disease.
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